Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients

Fluoroquinolones (levofloxacin (Lfx) and moxifloxacin) belong to the class A drugs for treating multidrug-resistant (MDR) tuberculosis (TB), which is characterised by resistance to both rifampicin and isoniazid [1]. The drugs have become a mainstay in both longer and shorter MDR-TB regimens, as well as isoniazid resistance [1, 2]. Despite this potential, currently used doses have become a major concern due to subtherapeutic concentrations achieved, leading to acquired drug resistance [3–5].

Source: European Respiratory Journal - April 17, 2019 Category: Respiratory Medicine Authors: Ghimire, S., Maharjan, B., Jongedijk, E. M., Kosterink, J. G. W., Ghimire, G. R., Touw, D. J., van der Werf, T. S., Shrestha, B., Alffenaar, J.-W. C. Tags: Original Articles: Research letters Source Type: research